Curis (CRIS) Analysts Reaffirm $14.00 Price Target Amid Changing Assumptions

Curis (CRIS) analysts reaffirm a $14.00 per share fair value despite shifting assumptions about execution risks, profitability, and valuation support. Monness Crespi raised its price target on Carter's to $45 and shifted to a Buy rating, while UBS raised its target to $40 and kept a Neutral rating. Goldman Sachs lifted its target to $29 but maintained a Sell rating. The company plans to seek shareholder approval to amend its Restated Certificate of Incorporation to increase authorized capital stock.